09.12.2019 15:04:04
|
Merck To Acquire ArQule For $20/share In Cash - Quick Facts
(RTTNews) - Biopharmaceutical company Merck (MRK), known as MSD outside the U.S. and Canada, agreed Monday to acquire, through a subsidiary, its peer ArQule, Inc. (ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion. The transaction is expected to close early in the first quarter of 2020.
ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases.
The acquisition of ArQule further diversifies Merck's oncology pipeline with expansion into targeted therapies that treat hematological malignancies.
ArQule's lead investigational candidate, ARQ 531, is a novel, oral Bruton's tyrosine kinase (BTK) inhibitor currently in a Phase 2 dose expansion study for the treatment of B-cell malignancies.
Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of ArQule at $20 per share.
The closing of the tender offer is primarily subject to the tender of shares representing at least a majority of the total number of ArQule's outstanding shares and other customary conditions. Upon the successful completion of the tender offer, Merck's acquisition subsidiary will be merged into ArQule.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
24.01.25 |
Dow Jones aktuell: Dow Jones gibt am Freitagmittag nach (finanzen.at) | |
21.01.25 |
Börse New York: Dow Jones zum Ende des Dienstagshandels mit Zuschlägen (finanzen.at) | |
21.01.25 |
Börse New York: Dow Jones steigt nachmittags (finanzen.at) | |
21.01.25 |
Freundlicher Handel: Dow Jones am Mittag stärker (finanzen.at) | |
21.01.25 |
Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor einem Jahr eingebracht (finanzen.at) | |
20.01.25 |
Erste Schätzungen: Merck gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
17.01.25 |
Börse New York: Dow Jones letztendlich im Plus (finanzen.at) | |
17.01.25 |
Gewinne in New York: Dow Jones bewegt sich nachmittags im Plus (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 90,60 | -0,55% |